Anti-Human C4d Antibody

$420.00

The Eagle Biosciences Anti-Human C4d antibody is described by the majority of publications as an important marker in kidney transplantation but also in heart, liver, and other transplants. Circulating alloantibodies encounter the grafted endothelium as the first target. Living endothelial cells can rapidly eliminate bound antibodies from the cell surface by “capping”, “shedding” or “internalisation”. C4d is the degradation product of the activated complement factor C4, a component of the classical complement cascade, which is typically initiated by binding of antibodies to specific target molecules. Detection of C4d is regarded as an indirect sign, a “footprint” of an antibody response against the allograft.

SKU: BI-RC4D Categories: ,

Anti-Human C4d Antibody

For Research Use Only

Quantity: 250 µl/vial
Source: Rabbit Polyclonal
Form: Liquid IgG fraction, purified by protein G chromatography
Immunogen: Synthetic peptide (15-mer peptide corresponding to aa 1242-1256 of C4) specific for human complement split product C4d coupled to KLH (keyhole limpet haemocyanine).
Specificity: The antibody will identify human complement split product C4d
Shelf Life: Expiration date stated on label.

Product Developed and Manufactured in Austria by Biomedica

Additional Information

Application

The antibody has been tested for use on paraffin sections and frozen sections of human tissue. Working protocol available. Recommended dilution for immunohistochemistry: 1:30 – 1:50 Pretreatment of slides by pressure cooking (5 minutes at +125°C in TRIS/EDTA buffer pH 8.5) is highly recommended for antigen retrieval.

 

 

 

 

 

 

 

 

 

 

 

Paraffin embedded tissue sections of Anti human C4d Antibody

Manual

Product Manual


Publications

References

BI-RC4D_Anti_C4d_References

  • Regele H et al. “Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection”.Nephrol Dial Transplant 2001, 16:2058-66
  • Böhmig GA et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol, 2001 Nov;12(11):2482-9
  • Böhmig GA et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol. 2002 Apr;13(4):1091-9.
  • Regele H et al. „Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular an glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection”. J Am Soc Nephrol. 2002, 13:2371-80